Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2012 1
2013 1
2015 1
2016 1
2018 1
2019 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N; RENACER; Valiente M. Monteiro C, et al. Nat Med. 2022 Apr;28(4):752-765. doi: 10.1038/s41591-022-01749-8. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411077 Free PMC article.
Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits.
Sanchez-Aguilera A, Masmudi-Martín M, Navas-Olive A, Baena P, Hernández-Oliver C, Priego N, Cordón-Barris L, Alvaro-Espinosa L, García S, Martínez S, Lafarga M; RENACER; Lin MZ, Al-Shahrour F, Menendez de la Prida L, Valiente M. Sanchez-Aguilera A, et al. Cancer Cell. 2023 Sep 11;41(9):1637-1649.e11. doi: 10.1016/j.ccell.2023.07.010. Epub 2023 Aug 30. Cancer Cell. 2023. PMID: 37652007 Free PMC article.
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.
Zhu L, Retana D, García-Gómez P, Álvaro-Espinosa L, Priego N, Masmudi-Martín M, Yebra N, Miarka L, Hernández-Encinas E, Blanco-Aparicio C, Martínez S, Sobrino C, Ajenjo N, Artiga MJ, Ortega-Paino E, Torres-Ruiz R, Rodríguez-Perales S; RENACER; Soffietti R, Bertero L, Cassoni P, Weiss T, Muñoz J, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Laín A, Toldos O, Ruano Y, Alcázar L, Blasco G, Fernández-Alén J, Caleiras E, Lafarga M, Megías D, Graña-Castro O, Nör C, Taylor MD, Young LS, Varešlija D, Cosgrove N, Couch FJ, Cussó L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M. Zhu L, et al. EMBO Mol Med. 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552. Epub 2022 Feb 17. EMBO Mol Med. 2022. PMID: 35174975 Free PMC article.
Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients.
Torrente-Segarra V, Fernández Prada M, Expósito R, Garrido Puñal NP, Sánchez-Andrade A, Lamúa-Riazuelo JR, Olivé A, Tovar JV; RENACER Study Group. Torrente-Segarra V, et al. Reumatol Clin (Engl Ed). 2021 Jan;17(1):57-58. doi: 10.1016/j.reuma.2018.12.004. Epub 2019 Jan 28. Reumatol Clin (Engl Ed). 2021. PMID: 30704922 Free article. English, Spanish. No abstract available.
RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database.
Torrente-Segarra V, Urruticoechea Arana A, Sánchez-Andrade Fernández A, Tovar Beltrán JV, Muñoz Jiménez A, Martínez-Cristóbal A, González Ferrández JA, Fernández Prada M, Vázquez Fuentes N, Corominas H, García-Díaz S, Acosta Pereira A, Ruiz Martín JM, Lamua Riazuelo JR, Expósito Moliner R, Ruiz Vilchez D, Veiga Cabello R, Fernández JC, Noguera Pons JR, Garrido Puñal NP, Giralt Celiméndiz P, Cortés Verdú R, Aragón Díez A, Tomás Roura C, Moll Turudi C, Taverner Torrent D, Rivas Santirso FJ, Lerma Garrido JJ, García Portales R, Ordoñez Palau S, Paredes González-Albo S, Gracia Pérez A, Conesa Mateos A, Calvo Alén J, Graña Gil J, Navarro Alonso MP, Martínez Blasco MJ; (RENACER StudyGroup). Torrente-Segarra V, et al. Mod Rheumatol. 2016 May;26(3):336-341. doi: 10.3109/14397595.2015.1101200. Epub 2015 Nov 7. Mod Rheumatol. 2016. PMID: 26418571
How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.
Torrente-Segarra V, Fernandez Prada M, Expósito Moliner R, Garrido Puñal NP, Sánchez-Andrade Fernández A, Lamua Riazuelo JR, Olivé A, Tovar Beltrán JV; RENACER Study Group (REgistro NAcional CERtolizumab). Torrente-Segarra V, et al. Rheumatol Int. 2019 Feb;39(2):395-398. doi: 10.1007/s00296-018-4205-z. Epub 2018 Nov 24. Rheumatol Int. 2019. PMID: 30474721 No abstract available.